2361162-70-9
2361162-70-9 structure
- Name: TCL053
- Chemical Name: TCL053
- CAS Number: 2361162-70-9
- Molecular Formula: C53H95NO8
- Molecular Weight: 874.32
- Catalog: Research Areas Neurological Disease
- Create Date: 2022-10-18 21:34:05
- Modify Date: 2026-08-02 13:26:49
-
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle[1][2].
| Name | TCL053 |
|---|
| Description | TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | TCL053 shows a dissociation constant pKa =6.8[1]. TCL053 : DPPC : Cholesterol : DMG-PEG =60 : 10.6 : 27.3 : 2.1, shows an encapsulation rate of 96%, and a size of 79.1 nM[1]. |
| In Vivo | TCL053-based LNP encapsulating Cas9 mRNA (TCL053-LNP-CRISPR) (20 µg total RNA; i.m.) exhibits high genome editing and exon skipping efficacy, and is higher than other in vivo mRNA delivery reagent (in vivo-jetRNA)[1]. TCL053-based LNP, via limb perfusion method, can target multiple muscle groups, with repeated administration and low immunogenicity features[1]. TCL053-based LNP acts as a delivery vehicle of CRISPR-Cas9 and can be used for skeletal muscle disorders research[1]. TCL053-based LNP induces stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence[1]. |
| References |
| Molecular Formula | C53H95NO8 |
|---|---|
| Molecular Weight | 874.32 |